Biopharma Milestone Payments Negotiating an Equitable Value Allocation
Immuno-Oncology Alliances Command Big Deal Premiums
Recent Trends & How Far You Can Go
Sharing the Wealth Recent Trends in Biopharma Sublicensing
The Best Biotech IPO Window ...That Money Can Buy!
Changing the Deal How Far Can You Go & How Often
Dawn of a Post-Venture Era: The New Face of Innovation & Translational Research
Effective Royalty Rates in Biopharma Alliances What They Are and Why Use Them in Negotiations
Yours, Mine & Ours Partnering Compounds Globally
Top Pharma Vs. Major Biotech Who is Biopharma’s Favorite Alliance Partner?
Orphan Drug Alliances
Co-Promotion in Biopharma Agreements Success is in the Details
Trends in University Licenses How Healthy is the Seed Corn?
The BioPharma Industry in 2015 As Good as it Gets
Duration of Royalty Obligations ’Til Death Do Us Part?
Re‐emergence of Platform Technologies Gonna Party Like It’s 1999
2014 Year in Review IPOs, Financings & Alliances
Sales Milestones Bridging the Valuation Gap
Demand Dividend A New Investment Vehicle for Financing Biotech Companies
Biotech IPOs Springboard for Success
Biotech Sell Side Research A Retrospective Analysis